Developmental Therapeutics Committee

 

Purpose

The Developmental therapeutics committee’s purpose is to support the design and development of novel Phase I and II studies to identify the dose, schedule and preliminary efficacy of novel therapeutic approaches with the goal to advance safe and effective novel therapies into Phase 2 and 3 studies. Our studies include traditional phase I and II studies, window-of-opportunity studies, neoadjuvant therapy studies, and novel therapeutic designs. We support the development of translational and correlative studies to advance the science behind these novel therapeutic options. We strive to educate, include and support (early) investigators in drug development, design and conduct of early phase clinical trials.

The full committee meets 2 times per year during the NRG Oncology semi-annual in-person meetings. The Core Committee additionally meets with two virtual interim meetings in between the semi-annual NRG Oncology meetings. Study-specific meetings occur on a weekly/bi-weekly basis, and depending on the phase of development.

Developmental Therapeutics Committee Leadership

Chair

Roisin O’Cearbhaill, MD

Vice Chair

Floor Backes, MD

Vice Chair

Andrés Álvarez-Pinzón
Working Groups

Hematologic Malignancy Working Group

Chair

Brad Hoppe

Co-Chairs

Margaret Kasner, Chelsea Pinnix

Core Committee Members
  • Sarah Adams
  • Jan Beumer
  • Bradley Corr
  • Katherine Fuh
  • Stephanie Gaillard
  • Eugenia Girda
  • Marilyn Huang
  • Amanda L. Jackson
  • Sarah Lynam
  • Cara Mathews
  • Karen McLean
  • Sanaz Memarzadeh
  • Debra Richardson
  • Fiona Simpkins
  • Andrea E. Wahner Hendrickson
  • Shannon Westin
  • Oladapo Yeku
  • Dmitriy Zamarin
  • Kristen P. Zeligs
General Committee Members
  • Laura Alder
  • Therese Youssef Andraos
  • Christina Annunziata
  • Deborah Armstrong
  • Adanma Anji Ayanambakkam Attanathi
  • Monica Avila
  • Kalyan Banda
  • Lisa Barroilhet
  • Elizabeth Dominic Barrows
  • Saveri Bhattacharya
  • Michael Bookman
  • William Bradley
  • Lindsay Brubaker
  • Lee-May Chen
  • Jennifer H. Choe
  • Madison L. Conces
  • Sarah E. Crafton
  • Erin Crane
  • Jennifer F. De Los Santos
  • Trisha Wise Draper
  • Marie Duclos
  • John Farley
  • Vaia Florou
  • Julia Foldi
  • Claire Friedman
  • Melissa Geller
  • Mridula A. George
  • Sharad Ghamande
  • Radhika Gogoi
  • Daniel Haldar
  • Catherine T. Haring
  • John Hays
  • Brian Henick
  • June Hou
  • Dharamvir Jain
  • Yong-Man Kim
  • Emily Kinssey
  • Megan L Kruse
  • Chrisann Kyi
  • Charles Landen
  • Jayanthi Lea
  • Daniel J. Lee
  • Elizabeth Lee
  • Shashikant Lele
  • Ken Lin
  • Joyce Liu
  • Haider Mahdi
  • Amit Mahipal
  • Stephanie Markovina
  • Jyoti Mayadev
  • Carolyn McCourt
  • Carolyn Moloney
  • Kathleen Moore
  • John Moroney
  • Fernanda Musa
  • Alexander Olawaiye
  • Brian Orr
  • Leslie Randall
  • Fauzia Riaz
  • Peter Rose
  • Masey M. Ross
  • Anwaar Saeed
  • Angeles Secord
  • Aditya Varnam Shreenivas
  • Jean Siedel
  • Travis T. Sims
  • Mihae Song
  • Jessica D. St. Laurent
  • Sarah E. Taylor
  • Candice N. Thompson
  • Bhandu Prasad Venkatesulu
  • Ding Wang
  • Mei Wei
  • Ira Winer
  • Oladapo Yeku
  • Janie Zhang
  • Yuanyuan Zhang
  • Qing C. Zhao
Resources


NRG Oncology Phase I Procedure Manual 
NRG Oncology Phase I Member Application

The NRG Oncology DT Subcommittees (Ph I and DT-RT) review applications annually and will update this page in accordance with scheduled review.

Protocol Development | CTEP (cancer.gov)

 

 

 

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.